← Back to patent-cliff list
Mitapivat sulfate
Tier C — Watch / tradeMitapivat sulfate
Agios Pharmaceuticals Inc
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Pyruvate kinase
Brand：Pyrukynd, Aqvesme
Indications (approved)：α-地中海贫血, Beta thalassaemia, 丙酮酸激酶缺乏症, Haemolytic anaemia
Regional status
US
Approved
2022-02-17
EU
Approved
2022-11-09
China
-
Japan
Phase III
2018-08-09
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mitapivat sulfate?
Approved indications include: α-地中海贫血, Beta thalassaemia, 丙酮酸激酶缺乏症, Haemolytic anaemia.
When does the Mitapivat sulfate patent expire?
No public expiry year is available for Mitapivat sulfate yet; this page updates once verified.
How do I get a quote for Mitapivat sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27